Mood and Performance Changes in Women with Premenstrual Dysphoric Disorder Acute Effects of Alprazolam

Evans, Suzette M.

doi:10.1016/s0893-133x(98)00064-5

Cited by 57 publications

(46 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since there is no evidence that PMDD women differ in the density or affinity of peripheral benzodiazepine receptors, at least as measured on lymphocytes (Daly et al, 2001), the findings of Sundstrom and colleagues indicate diminished functional sensitivity of GABA A receptors in PMDD. This is consistent with studies finding modest or no clinical efficacy with benzodiazepine treatment for PMDD (Schmidt et al, 1993;Freeman et al, 1995;Evans et al, 1998), though exceptions exist (Harrison et al, 1987), and with lack of clinical benefit associated with a progesterone intervention or with progesterone induction of supraphysiologic levels of 5α-and 5β-progesterone metabolites Vanselow et al, 1996;see Wyatt et al, 2001 for review). It is also consistent with the results of a placebo-controlled clinical trial of antidepressants that found that PMDD women who were classified as "improved" with treatment had significantly lower, and not higher, plasma allopregnanolone concentrations at post-treatment than PMDD women who did not improve (Freeman et al, 2002).…”

Section: Hpa Axis and Gaba A Receptor Function In Pmddsupporting

confidence: 72%

Neurosteroids in the context of stress: Implications for depressive disorders

Girdler

Klatzkin

2007

Pharmacology & Therapeutics

129

View full text Add to dashboard Cite

Animal models indicate that the neuroactive steroids 3α,5α-THP (allopregnanolone) and 3α,5α-THDOC (allotetrahydroDOC) are stress responsive, serving as homeostatic mechanisms in restoring normal GABAergic and hypothalamic-pituitary-adrenal (HPA) function following stress. While neurosteroid increases to stress are adaptive in the short term, animal models of chronic stress and depression find lower brain and plasma neurosteroid concentrations and alterations in neurosteroid responses to acute stressors. It has been suggested that disruption in this homeostatic mechanism may play a pathogenic role in some psychiatric disorders related to stress. In humans, neurosteroid depletion is consistently documented in patients with current depression and may reflect their greater chronic stress. Women with the depressive disorder, premenstrual dysphoric disorder (PMDD), have greater daily stress and a greater rate of traumatic stress. While results on baseline concentrations of neuroactive steroids in PMDD are mixed, PMDD women have diminished functional sensitivity of GABA A receptors and our laboratory has found blunted allopregnanolone responses to mental stress relative to non-PMDD controls. Similarly, euthymic women with histories of clinical depression, which may represent a large proportion of PMDD women, show more severe dysphoric mood symptoms and blunted allopregnanolone responses to stress versus never-depressed women. It is suggested that failure to mount an appropriate allopregnanolone response to stress may reflect the price of repeated biological adaptations to the increased life stress that is well documented in depressive disorders and altered allopregnanolone stress responsivity may also contribute to the dysregulation seen in HPA axis function in depression.

show abstract

Section: Hpa Axis and Gaba A Receptor Function In Pmddsupporting

confidence: 72%

Neurosteroids in the context of stress: Implications for depressive disorders

Girdler

Klatzkin

2007

Pharmacology & Therapeutics

129

View full text Add to dashboard Cite

show abstract

“…These dramatic cyclical changes in mood in women with PMDD have been well documented both clinically and in research studies (e.g. De Ronchi et al, 2005;Evans et al, 1998;Freeman et al 1985;Halbreich et al 1982;Landen et al, 2007;Rapkin et al 1989). …”

Section: Introductionmentioning

confidence: 84%

“…Another study (Morgan and Rapkin, 2002) that also assessed a full series of neurocognitive tasks reported no performance differences between women with PMDD and control women, despite a relatively large sample size. In a previous study conducted in our laboratory (Evans et al, 1998), we assessed changes in mood and performance as a function of menstrual cycle phase in women with confirmed PMDD after placebo or alprazolam administration. When placebo was administered, motor coordination (via a balance task) and performance on the Digit Symbol Substitution Task (DSST) were impaired in the luteal phase.…”

Section: Introductionmentioning

confidence: 99%

“…Limitations of that study included only administering placebo one day in each phase and the lack of a control group. Regardless, one major distinction between the Evans et al (1998) study and all the other studies mentioned above is that task performance was assessed multiple times over the day, not just once. The fact that most previous studies only assessed performance on a single occasion each phase may be one reason for the inconsistencies observed across studies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of the menstrual cycle in women with and without PMDD (premenstrual dysphoric disorder)

Reed

Levin

Evans

2008

Hormones and Behavior

140

View full text Add to dashboard Cite

Although it's been reported that women with premenstrual dysphoric disorder (PMDD) have increased negative mood, appetite (food cravings and food intake), alcohol intake and cognitive deficits premenstrually, few studies have examined these changes concurrently within the same group of women or compared to women without PMDD. Thus, to date, there is not a clear understanding of the full range of PMDD symptoms. The present study concurrently assessed mood and performance tasks in 29 normally cycling women (14 women who met DSM-IV criteria for PMDD and 15 women without PMDD). Women had a total of ten sessions: two practice sessions, 4 sessions during the follicular phase and 4 sessions during the late luteal phase of the menstrual cycle. Each session, participants completed mood and food-related questionnaires, a motor coordination task, performed various cognitive tasks and ate lunch. There was a significant increase in dysphoric mood during the luteal phase in women with PMDD compared to their follicular phase and compared to Control women. Further, during the luteal phase, women with PMDD showed impaired performance on the Immediate and Delayed Word Recall Task, the Immediate and Delayed Digit Recall Task and the Digit Symbol Substitution Test compared to Control women. Women with PMDD, but not Control women, also showed increased desire for food items high in fat during the luteal phase compared to the follicular phase and correspondingly, women with PMDD consumed more calories during the luteal phase (mostly derived from fat) compared to the follicular phase. In summary, women with PMDD experience dysphoric mood, a greater desire and actual intake of certain foods and show impaired cognitive performance during the luteal phase. An altered serotonergic system in women with PMDD may be the underlying mechanism for the observed symptoms; correspondingly, treatment with specific serotonin reuptake inhibitors (SSRIs) remains the preferred treatment at this time.

show abstract

“…To assess delayed free recall, participants repeated this task 210 min later. This was followed by a recognition test, in which participants had to identify the 12 words shown earlier from a list containing 48 words (Evans et al, 1998).…”

Section: Methods Study 1: Marijuana Smokersmentioning

confidence: 99%

Opioid Antagonism of Cannabinoid Effects: Differences between Marijuana Smokers and Nonmarijuana Smokers

Haney

2006

Neuropsychopharmacol

102

View full text Add to dashboard Cite

In non-human animals, opioid antagonists block the reinforcing and discriminative-stimulus effects of D 9 -tetrahydrocannabinol (THC), while in human marijuana smokers, naltrexone (50 mg) enhances the reinforcing and subjective effects of THC. The objective of this study was to test a lower, more opioid-selective dose of naltrexone (12 mg) in combination with THC. The influence of marijuana-use history and sex was also investigated. Naltrexone (0, 12 mg) was administered 30 min before oral THC (0-40 mg) or methadone (0-10 mg) capsules, and subjective effects, task performance, pupillary diameter, and cardiovascular parameters were assessed in marijuana smoking (Study 1; n ¼ 22) and in nonmarijuana smoking (Study 2; n ¼ 21) men and women. The results show that in marijuana smokers, low-dose naltrexone blunted the intoxicating effects of a low THC dose (20 mg), while increasing ratings of anxiety at a higher THC dose (40 mg). In nonmarijuana smokers, low-dose naltrexone shifted THC's effects in the opposite direction, enhancing the intoxicating effects of a low THC dose (2.5 mg) and decreasing anxiety ratings following a high dose of THC (10 mg). There were no sex differences in these interactions, although among nonmarijuana smokers, men were more sensitive to the effects of THC alone than women. To conclude, a low, opioid-selective dose of naltrexone blunted THC intoxication in marijuana smokers, while in nonmarijuana smokers, naltrexone enhanced THC intoxication. These data demonstrate that the interaction between opioid antagonists and cannabinoid agonists varies as a function of marijuana use history.

show abstract

Mood and Performance Changes in Women with Premenstrual Dysphoric Disorder Acute Effects of Alprazolam

Abstract: This study determined if women with premenstrual dysphoric disorder (PMS) showed impaired mood and

Cited by 57 publications

References 47 publications

Neurosteroids in the context of stress: Implications for depressive disorders

Neurosteroids in the context of stress: Implications for depressive disorders

Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of the menstrual cycle in women with and without PMDD (premenstrual dysphoric disorder)

Opioid Antagonism of Cannabinoid Effects: Differences between Marijuana Smokers and Nonmarijuana Smokers

Contact Info

Product

Resources

About